Skip to main content

Table 1 Basic characteristics of breast cancer patients from the study sample

From: The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma

Basic demographic & clinical characteristics FEC (n = 73) FEC-T (n = 60) All regimens (n = 161) a
Age range (years) 28-63 27-65 21-65
Disease stage, n (%) metastatic 12 (16) 1 (2) 20 (12)
Bone metastasis, n (%) 7 (10) 0 (0) 12 (7)
HER status, n (%) positive 17 (23) 25 (42) 53 (33)
Prior/concomitant surgery, n (%) 67 (92) 53 (88) 145 (90)
Prior/concomitant radiotherapy, n (%) 49 (67) 40 (67) 111 (69)
Prior/concomitant hormone therapy, n (%) 42 (58) 33 (55) 90 (56)
  1. Basic demographic and clinical characteristics of the breast cancer patients are presented for the two most frequent chemotherapy regimens, and all regimens.
  2. aOther regimens used in the sample but not displayed were docetaxel (n = 9), AC → T (n = 5), capecitabine/docetaxel (n = 2), capecitabine/docetaxel/trastuzumab (n = 2), docetaxel/trastuzumab (n = 2), epirubicin/cyclophosphamide (n = 2), FEC/trastuzumab (n = 2) and capecitabine/larotaxel, doxorubicin/docetaxel, epirubicin/docetaxel, epirubicin/cyclophosphamide/larotaxel (1 patient each)